Hayward, California – December 16, 2015 – Advanced Cell Diagnostics, Inc. (ACD), a world leader in RNA biomarker analysis for precision medicine, announces the appointment of Robert J. Monroe, M.D., Ph.D., to its executive leadership team as Chief Medical Officer.
Board certified in anatomic pathology, clinical pathology, and cytopathology, Dr. Monroe has demonstrated a record of success providing medical leadership for companies in the clinical diagnostics industry. Most recently, he served as Medical Director and Vice President of Laboratory Operations for Veracyte (VCYT), a diagnostics company focused on molecular cytology, where he led the company’s CLIA laboratories, including oversight of the highly successful Afirma® Thyroid FNA Analysis and recent launch of the PerceptaTM Bronchial Genomic Classifer. Prior to Veracyte, Dr. Monroe served as Chief Medical Officer of BioImagene (acquired by Ventana, a member of the Roche Group, in 2010), a leading provider of imaging solutions for anatomic pathology and clinical diagnostics where he headed the company’s efforts to develop software applications for pathologists, including multiple FDA-cleared algorithms for immunohistochemistry analysis. Dr. Monroe was also Co-Founder and Chief Medical Officer of OncoMDx, a Palo Alto-based molecular diagnostics laboratory later acquired by CORE Diagnostics to support expansion of next generation diagnostics in India.
“ACD and its RNAscope technology have already established a leadership position in translational research and increasingly become a major platform for the development of diagnostic and companion diagnostic tests. I’m very excited to build on this success and help the company enter the clinical market with novel applications intended to improve diagnosis and guide treatment,” said Dr. Monroe.
“ACD’s vision is to bring the power of molecular diagnostics to pathologists,” said Dr. Yuling Luo, President and CEO of ACD. “Dr. Monroe’s unique experience at the intersection of biotechnology, clinical diagnostics, and anatomic pathology makes him an ideal person to lead ACD’s efforts to develop high value clinical diagnostics,” Dr. Luo continued.
About Advanced Cell Diagnostics
Advanced Cell Diagnostics, Inc. (ACD) is a world leader in RNA biomarker analysis for precision medicine, providing the world’s most advanced RNA analysis solutions for cell and tissue based diagnostics in molecular pathology. Its proprietary award-winning RNAscope® technology is capable of detecting and quantifying RNA biomarkers with single-molecule sensitivity and single-cell resolution in routine clinical specimens. The technology has been employed in hundreds of peer-reviewed publications by a rapidly growing customer base of thousands of active users, including all of the global top pharmaceutical companies, many cutting-edge biotechnology companies, and world-leading academic institutions. ACD builds strategic alliances with its customers and partners to develop companion diagnostic tests for existing and emerging therapeutics. ACD also pursues internal programs to develop and commercialize proprietary cancer diagnostic tests. Learn more about ACD and RNAscope technology at www.acdbio.com.
